Cargando…
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Immunologists
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049585/ https://www.ncbi.nlm.nih.gov/pubmed/32158591 http://dx.doi.org/10.4110/in.2020.20.e3 |